Development of Novel Antimalarial Drugs

Bio21 Molecular Science and Biotechnology Institute
Primary Supervisor Email Number Webpage
Prof Leann Tilley

Summary The Tilley lab is working as part of a global effort to understand and control malaria. We undertake research in the areas of cell biology and drug development related to the malaria parasite, Plasmodium falciparum. We investigate the action of and resistance to artemisinin, and are working to design better antimalarial drugs.

Project Details

Would you like to help develop new antimalarial drugs?  Each year, Plasmodium falciparum causes more than 200 million cases of malaria, and about 438,000 deaths. Because current antimalarial control is highly dependent on artemisinin combination therapies (ACTs), it is extremely concerning that decreased sensitivity has emerged to all currently used ACTs. In response to this impending crisis, the peak body, Medicines for Malaria Venture (MMV), has declared that novel targets for antimalarial therapies need to be identified and new drugs developed. 

School Research Themes

Cell Signalling

Key Contact

For further information about this research, please contact a supervisor.

Research Node

Bio21 Molecular Science and Biotechnology Institute

MDHS Research library
Explore by researcher, school, project or topic.